In this study, we identified factors associated with worsening of pre-existing ILD in RA patients treated with JAKi or bDMARDs and, further, examined the impact of JAKi and MTX pre-treatment on IL-6-induced EMT in A549 cells in vitro, thereby providing new insights into therapeutic strategies for patients with RA-ILD. This evidence concerns the gene IL6 and rheumatoid arthritis.